
Acadia Pharmaceuticals fell 21.9% from $24.01 to $18.75, behind the S&P 500's +11.2%. Its worst day was Nov 9 (−22.3%), and its low came Nov 9 at $16.50.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.14 beat the $0.13 estimate on $284.0M revenue (est. $292.5M); FY revenue guidance of $1.2B–$1.3B against the $1.2B consensus.
−1.3% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
EPS of $0.02 missed the $0.07 estimate on $268.1M revenue (est. $280.6M); FY revenue guidance of $1.2B–$1.3B against the $1.2B consensus.
+5.0% · S&P 500 −0.3%
EPS of $0.18 beat the $0.04 estimate on $308.0M revenue (est. $295.2M); FY revenue guidance of $1.2B–$1.3B against the $1.2B consensus.
+6.1% · S&P 500 −0.2%
Acadia Pharmaceuticals closed at its highest level of the year, 27.3% above where the year started.
+3.1% · S&P 500 +0.3%
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary
−12.8% · S&P 500 −0.1%
EPS of $0.31 beat the $0.18 estimate on $342.3M revenue (est. $333.0M); FY revenue guidance of $1.3B–$1.3B against the $1.3B consensus.
−1.1% · S&P 500 −4.4%
Where it ended: a close of $18.75 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $0.27, revenue est. $363.4M).
Nothing in the past 12 months.
All ACAD dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ACAD and SPY from Benzinga historical bars. Not investment advice.